Yesterday, Johnson & Johnson, the pharmaceutical giant and US medical, has released its second-quarter earning reports. Profit are above analysts’ expectations, further enhancing its estimates. Quarterly net income totaled $ 4.5 billion and $ 1.61 per share, compared to $ 4.3 billion and $ 1.51 per share, a year ago, thanks to with strong performance being driven by robust growth in its pharmaceutical business and reliable performance of its consumer brands. The adjusted EPS came in at $ 1.71, against a consensus of $ 1.68. Sales decreased by almost 9% to $ 17.8 billion, as expected, since the consensus was of $17.76 billion. Sales declined 2.4% in the US and 14% internationally. Currency effects were negative by 8%.
For the year, J&J revises its forecast EPS in the range of $6.10 to $ 6.20, compared to $6.04 to $6.19 previously envisaged.